alfuzosin has been researched along with Adenoma, Prostatic in 186 studies
alfuzosin: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effects of alfuzosin hydrochloride and tamsulosin hydrochloride on choroidal thickness (CT) and pupil diameter (PD) sizes in patients with benign prostatic hyperplasia." | 9.24 | The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases with Benign Prostatic Hyperplasia. ( Dogan, M; Halat, AO; Karalar, M; Keles, I; Kutluksaman, B, 2017) |
| "The objective of this study was to assess the efficacy and safety of alfuzosin 10 mg monotherapy or combined antihypertensive medication on blood pressure (BP) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS) with or without antihypertensive medication." | 9.20 | Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive med ( Chung, WS; Hyun, JS; Kim, SW; Lee, SW; Min, KS; Moon, DG; Moon, KH; Park, JK; Park, K; Ryu, JK; Yang, DY; Yang, SK; Zhang, LT, 2015) |
| "The aim of this study was to assess patient outcome after discontinuation of alfuzosin treatment in patients with benign prostatic hyperplasia (BPH)." | 9.17 | Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study. ( Chung, JH; Han, JH; Jo, JK; Kang, DH; Kim, TH; Lee, JW; Lee, JY; Lee, KS; Lee, SH; Lee, SW, 2013) |
| "The aim of this study was to compare the efficacy and safety of alfuzosin (Alf) and tamsulosin (Tam) in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)." | 9.15 | Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia. ( Atahan, Ö; Budak, YU; Karadağ, E; Öner, S, 2011) |
| "To compare the efficacy of Alfuzosin XL 10 mg once daily for the acute management of acute urinary retention (AUR) with placebo in patients with benign prostatic hyperplasia (BPH) and to determine the predictors that impact this." | 9.14 | Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. ( Consigliere, D; Li, MK; Macalalag, M; Tibung, MJ; Tiong, HY, 2009) |
| "To evaluate the effect of alfuzosin 10 mg once daily administered for 2 years on progression events in men with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH)." | 9.12 | Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. ( Roehrborn, CG, 2006) |
| "To determine the efficacy and safety of the selective alpha(1)-blocker alfuzosin in men with lower urinary tract symptoms (LUTS) and painful ejaculation, compared with those with LUTS only, as painful ejaculation is one of the most prevalent, differentiating and bothersome symptoms in men with chronic prostatitis/chronic pelvic pain syndrome." | 9.12 | The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. ( Elhilali, M; Emberton, M; Nickel, JC; Vallancien, G, 2006) |
| "This randomized, double-blind, placebo-controlled study was conducted to investigate whether alfuzosin 10 mg once daily improves the maximum flow rate (Q(max)) and lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH) after 1 week and 1 month of treatment." | 9.12 | Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. ( Resnick, MI; Roehrborn, CG, 2007) |
| "This pilot study was undertaken to assess the efficacy and safety of the alpha(1)-blocker alfuzosin 10mg once daily (OD), the PDE-5 inhibitor sildenafil 25mg OD, and the combination of both on lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and erectile dysfunction (ED)." | 9.12 | Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. ( Gonzalez, RR; Kaplan, SA; Te, AE, 2007) |
| "To study the impact of alfuzosin 10 mg once daily (OD) on the outcome of a trial without catheter (TWOC) after a first episode of acute urinary retention (AUR) related to benign prostatic hyperplasia (BPH) and the subsequent management of BPH in these patients." | 9.11 | Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. ( Hargreave, TB; McNeill, SA; Roehrborn, CG, 2005) |
| "A new patented prolonged release formulation of the alpha1-adrenoceptor antagonist alfuzosin has been developed for once-daily (OD) administration in benign prostatic hyperplasia (BPH)." | 9.10 | Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects. ( Ahtoy, P; Chrétien, P; Delfolie, A; Dupain, T; Rauch, C; Rouchouse, A, 2002) |
| "The blood and prostatic concentrations of alfuzosin were determined in patients with benign prostatic hyperplasia (BPH)." | 9.10 | Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. ( Bressolle, F; Costa, P; Delmas, V; Mottet, N; Robert, M, 2003) |
| "To examine the efficacy and safety of a once-daily formulation of alfuzosin in a pooled analysis of three parallel, randomized, double-blind, placebo-controlled 3-month studies of patients with lower urinary tract symptoms (LUTS) consistent with clinical benign prostatic hyperplasia." | 9.10 | Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. ( Nordling, J; Roehrborn, CG; Van Kerrebroeck, P, 2003) |
| "Together, our findings suggest that alfuzosin OD exhibits a urodynamically measurable effect on bladder outlet obstruction due to benign prostatic hyperplasia in men with lower urinary tract symptoms within hours of the first administration." | 9.10 | First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. ( Forrest, J; Gittelman, M; Jacobs, S; Kim, D; Marks, LS; Roehrborn, CG, 2003) |
| ") prolonged-release formulation of the clinically uroselective alpha1-blocker, alfuzosin, in patients with symptomatic benign prostatic hyperplasia (BPH)." | 9.10 | Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. ( Jardin, A; Laval, KU; van Cangh, P; van Kerrebroec, P, 2002) |
| "To establish whether the administration of sustained-release (SR) alfuzosin improves the outcome of a trial without catheter (TWOC) after an episode of acute urinary retention." | 9.09 | Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled. ( Daruwala, PD; Hargreave, TB; McNeill, SA; Mitchell, ID; Shearer, MG, 1999) |
| "As we have previously published 4 articles reporting the treatment of 7,093 clinical benign prostatic hyperplasia (BPH) patients treated with alfuzosin in a 3-month open-labelled study which was subsequently extended to 12, 24, and 36 months, the objective of this article is to provide additional data on dropouts, acute urinary retention (AUR), progression to surgery, and safety under the natural conditions of general practice, paying special attention to the predictive factors." | 9.09 | History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. ( Comet, D; Grange, JC; Lukacs, B; McCarthy, C, 2000) |
| "To assess the efficacy and safety of a new prolonged release formulation of the uroselective alpha(1)-blocker alfuzosin for a once-daily dosing regimen in patients with lower urinary tract symptoms (LUTS) suggestive of symptomatic benign prostatic hyperplasia (BPH)." | 9.09 | Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. ( Jardin, A; Laval, KU; van Cangh, P; van Kerrebroeck, P, 2000) |
| "This general practitioner-run study assess the security as well as the efficacy and impact on health-related quality of life of a sustained-release (SR) form of alfuzosin in Spanish patients suffering from lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)." | 9.09 | Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice. ( Alfaro, V; Badiella, L; Fernández-Hernando, N; Guil, M; Sánchez-Chapado, M, 2000) |
| "To assess the effect of the age of patients with benign prostatic hyperplasia (BPH) on the clinical uroselectivity of alfuzosin during general medical practice." | 9.09 | The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ( Alfaro, V; Badiella, LI; Fernández-Hernando, N; Guil, M; Sánchez-Chapado, M, 2000) |
| "To assess the efficacy and safety, and determine the optimal dosage, of a once-daily (OD) formulation of the clinically uroselective alpha(1)-blocker, alfuzosin, in patients with lower urinary tract symptoms and symptomatic benign prostatic hyperplasia." | 9.09 | Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. ( Roehrborn, CG, 2001) |
| "To investigate in men with benign prostatic hyperplasia (BPH) treated in the general practitioner setting (1) the magnitude and durability of symptom score improvement with alfuzosin; (2) the effect on patients perceived health-related quality of life (HRQL) and sexuality, (3) adverse outcomes and treatment failure; and (4) progression to acute urinary retention and prostate surgery." | 9.08 | Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. ( Jardin, A; Leplège, A; Lukacs, B; Thibault, P, 1996) |
| "To assess the efficacy and safety of a sustained-release (SR) formulation of alfuzosin, a selective alpha(1)-blocker, in patients with symptomatic benign prostatic hyperplasia (BPH)." | 9.08 | Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. ( Buzelin, JM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Roth, S, 1997) |
| "The objective of this double-blind, placebo-controlled urodynamic pressure/flow study was to assess the efficacy of short-term treatment with the alpha 1-blocker alfuzosin in outflow obstruction of patients with symptomatic benign prostatic hyperplasia (BPH)." | 9.08 | Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. ( Casadei, G; Colombo, R; Di Silverio, F; Giberti, C; Martorana, G; Pacifico, P; Rigatti, P; von Heland, M, 1997) |
| "To compare the efficacy and tolerability of the alpha 1 A-subtype selective drug tamsulosin with the nonsubtype-selective agent alfuzosin in the treatment of patients with lower urinary tract symptoms (LUTS) suggestive of bladder outlet obstruction (BOO), often termed symptomatic benign prostatic hyperplasia (BPH)." | 9.08 | Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. ( Buzelin, JM; Fonteyne, E; Khan, A; Kontturi, M; Witjes, WP, 1997) |
| "Alfuzosin, a selective alpha 1-adrenoceptor antagonist which is effective in the symptomatic treatment of benign prostatic hyperplasia (BPH), was compared with prazosin, another drug commonly used for the same purpose." | 9.07 | Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. ( Blondin, P; Buzelin, JM; Hebert, M, 1993) |
| "In order to assess the efficacy and safety of alfuzosin, a selective alpha-1 receptor antagonist, 205 patients with Benign Prostatic Hyperplasia (BPH) were randomly assigned in a double-blind, placebo-controlled manner, to receive either alfuzosin 2." | 9.07 | Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group. ( Hansen, BJ; Mensink, HJ; Meyhoff, HH; Nordling, J; Walter, S, 1994) |
| "To address the long-term results of alfuzosin, an alpha 1-antagonist, in patients with benign prostatic hyperplasia (BPH)." | 9.07 | Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. ( Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A; Stalla-Bourdillon, A, 1994) |
| "The effects of alfuzosin, a potent alpha 1-blocker, were assessed in patients with benign prostatic hyperplasia, in a double-blind, multicenter, placebo-controlled, cross-over study." | 9.07 | Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group. ( De Sy, W; Santoni, JP; Schulman, CC; Tomas, M; Vandendris, M, 1994) |
| "In order to assess the efficacy and safety of alfuzosin, an alpha-1 blocker, in symptomatic patients with benign prostatic hyperplasia (BPH), 131 patients who had completed a 6-month placebo-controlled trial conducted on parallel groups entered a 12-month open study; 122 patients were treated with alfuzosin for 12 months and 56 patients for 18 months." | 9.07 | Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group. ( Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A, 1993) |
| " Search terms included benign prostatic hyperplasia, alfuzosin, treatment, alpha(1)-adrenergic receptor blocker, long-term, followup, lower urinary tract symptoms, complications or adverse events, sexual, retention and cardiovascular." | 8.83 | Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. ( McVary, KT, 2006) |
| "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of alfuzosin hydrochloride in the treatment of benign prostatic hyperplasia (BPH) are discussed." | 8.82 | Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. ( Lee, M, 2003) |
| "Extended-release (ER) alfuzosin hydrochloride is the most recently approved alpha-adrenergic receptor antagonist (AARA) for the management of symptomatic benign prostatic hyperplasia (BPH)." | 8.82 | Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. ( Guay, DR, 2004) |
| "To evaluate the efficacy and adverse effects of alfuzosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH)." | 8.82 | Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. ( MacDonald, R; Wilt, TJ, 2005) |
| "A pooled analysis was conducted in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia to examine the relationship between the postvoid residual urine (PVR) volume and various clinical characteristics and to assess the effect of alfuzosin, a clinically uroselective alpha(1)-blocker, on PVR volume and any other associated outcome." | 8.81 | Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. ( Geffriaud-Ricouard, C; Hargreave, TB; McNeill, SA; Roehrborn, CG; Santoni, J, 2001) |
| "The efficacy of alfuzosin in improving lower urinary tract symptoms and relieving bladder outlet obstruction has been demonstrated in numerous short- and long-term placebo-controlled studies and large-scale open studies, involving over 16,000 patients with symptomatic benign prostatic hyperplasia (BPH)." | 8.80 | Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia. ( Kirby, RS, 1998) |
| "To study the efficiency of using alfuzosin 10 mg (Alfuprost MR, SUN Pharma) in routine clinical practice in order to predict its feasibility for treating acute urinary retention." | 7.96 | [The use of alfuzosin in the treatment of patients with acute urinary retention]. ( Ergakov, DV; Martov, AG, 2020) |
| "To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >8 (range of scores, 0-35), and sexual attempts at least once per month were enrolled." | 7.78 | Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia. ( Chang, HC; Chen, CS; Chen, WH; Chiang, PH; Chu, SH; Hwang, TI; Lee, LM; Lin, MS; Yeh, SD, 2012) |
| "We report on 1 case of alfuzosin induced thrombocytopenia after treatment for benign prostatic hyperplasia." | 7.76 | Alfuzosin induced thrombocytopenia after treatment for benign prostatic hyperplasia. ( Güner, E; Güner, S; Mutlu, B; Taşçi, AI, 2010) |
| "Assess safety and efficacy of 10-mg prolonged-release alfuzosin (Xatral XL) in benign prostatic hyperplasia (BPH) patients with lower urinary tract symptoms (LUTS)." | 7.75 | Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ( Chodchoy, V; Kongkanand, A; Lojanapiwat, B; Pumpaisanchai, S; Ratana-Olarn, K; Sae-Tang, P; Taweemonkongsap, T, 2009) |
| "To compare the incidence of intraoperative floppy-iris syndrome (IFIS) in men exposed to tamsulosin and men exposed to alfuzosin and evaluate the effect of IFIS on the complication rate of cataract surgery." | 7.74 | Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin. ( Blouin, J; Blouin, MC; Dragomir, A; Lapointe, A; Perreault, S, 2007) |
| "The construction and characterization of potentiometric membrane electrodes are described for the quantification of alfuzosin, a drug used in a mono- and combined therapy of benign prostatic hyperplasia (BPH)." | 7.74 | Potentiometric sensors enabling fast screening of the benign prostatic hyperplasia drug alfuzosin in pharmaceuticals, urine and serum. ( Gupta, B; Gupta, VK; Singh, AK, 2007) |
| "To assess the 3-year efficacy and safety of the selective alpha(1)-blocker alfuzosin at 10 mg once daily in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in 'real-life practice'." | 7.74 | Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ, 2008) |
| "To calculate the economic consequences of using alfuzosin 10 mg once daily for managing acute urinary retention (AUR) related to benign prostatic hyperplasia (BPH)." | 7.73 | The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis. ( Annemans, L; Cleemput, I; Hargreave, T; Lamotte, M; McNeill, A, 2005) |
| "We analyzed the influence of treatment response on the risk of acute urinary retention and benign prostatic hyperplasia related surgery in 5,792 men complaining of lower urinary tract symptoms who were treated for 6 months with the selective alpha1-blocker alfuzosin at 10 mg once daily." | 7.73 | Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. ( Alcaraz, A; Elhilali, M; Emberton, M; Lukacs, B; Matzkin, H; Vallancien, G, 2006) |
| "40 patients with benign prostatic hyperplasia (BPH) were treated with the alpha-blocker alfuzosin which was administered per os twice a day in a dose 5 mg." | 7.69 | [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin]. ( Matushevskiĭ, IA; Mazo, EB; Nikitin, IuIu, 1997) |
| "Treatment with alfuzosin 10 mg significantly improved urinary symptoms and Qmax compared with placebo and was well tolerated." | 6.71 | Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. ( Nordling, J, 2005) |
| "Alfuzosin was well tolerated: the qualitative and quantitative distribution of adverse effects was identical to that previously observed in placebo-controlled trials (vertigo-dizziness: 2." | 6.69 | [Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years wi alfuzosin in general practice. BPH Group in General Practice]. ( Comet, D; Grange, JC; Lukacs, B; Mc Carthy, C, 1999) |
| "Silodosin is a novel, more selective alpha-blocker, which is specific to the lower urinary tract and may have fewer side effects than other alpha-blockers." | 6.55 | Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. ( Dahm, P; Jung, JH; Kim, J; Kim, MH; MacDonald, R; Reddy, B, 2017) |
| "Alfuzosin is a uroselective alpha(1)-blocker that relaxes the smooth muscle of the bladder neck and prostate gland to alleviate BPH symptoms." | 6.43 | Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia. ( Kuritzky, L; Rosenberg, MT; Sadovsky, R, 2006) |
| " No dosage titration is required." | 6.41 | Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. ( McKeage, K; Plosker, GL, 2002) |
| " A limited range of clinical studies have shown oral alfuzosin to be more effective than placebo (in studies of < or = 6 months duration), to have sustained effects on long term administration (< or = 30 months), and to be comparable with the alpha 1-adrenoceptor antagonist prazosin, in the symptomatic treatment of benign prostatic hyperplasia." | 6.38 | Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. ( Fitton, A; McTavish, D; Wilde, MI, 1993) |
| " The follow-up included 3 visits: visit of inclusion in the program of patients with a previously prescribed drug of Alfuprost MR in a dosage of 10 mg once a day (visit "0"), visit 1 at 30 days (+/-5 days) later, and visit 2 at 90 days (+/-5 days) after inclusion in the study." | 5.72 | [The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)]. ( Bernikov, AN; Loran, OB; Pushkar, DY, 2022) |
| "Incidence of benign prostatic hyperplasia (BPH), one of the most common conditions affecting adult men, increases dramatically after the age of 50." | 5.42 | [Impact of alfuzosin 10 mg once daily on quality of life in Tunisian patients with lower urinary symptoms suggestive of benign prostatic hyperplasia]. ( Adbi, H; Ben Raies, N; Ben Rhouma, S; Binous, MY; H'sairi, M; Horchani, A; Mosbah, AT; Nouira, Y, 2015) |
| "A novel slow release formulation of alfuzosin should improve compliance by reducing dosing to one 10 mg tablet per day." | 5.33 | Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin. ( Casey, R; Elhilali, M; Kuzmarov, I; Nickel, JC; Saad, F; Valiquette, L, 2005) |
| "To compare the effects of alfuzosin hydrochloride and tamsulosin hydrochloride on choroidal thickness (CT) and pupil diameter (PD) sizes in patients with benign prostatic hyperplasia." | 5.24 | The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases with Benign Prostatic Hyperplasia. ( Dogan, M; Halat, AO; Karalar, M; Keles, I; Kutluksaman, B, 2017) |
| "The objective of this study was to assess the efficacy and safety of alfuzosin 10 mg monotherapy or combined antihypertensive medication on blood pressure (BP) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS) with or without antihypertensive medication." | 5.20 | Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive med ( Chung, WS; Hyun, JS; Kim, SW; Lee, SW; Min, KS; Moon, DG; Moon, KH; Park, JK; Park, K; Ryu, JK; Yang, DY; Yang, SK; Zhang, LT, 2015) |
| "To compare the efficacy and safety of tamsulosin and alfuzosin in patients with acute urinary retention (AUR) secondary to benign prostatic hyperplasia (BPH)." | 5.19 | A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth. ( Carrillo-Ruiz, JD; González-Valle, JC; Guzman-Esquivel, J; Labra-Salgado, IR; Maldonado-Ávila, M; Manzanilla-García, HA; Rosas-Nava, E; Sierra-Ramírez, JA, 2014) |
| "To compare the efficacy and safety of single (tamsulosin) and double dose (tamsulosin + alfuzosin) alpha-blocker therapy for treating catheterized patients with acute urinary retention (AUR) due to benign prostatic hyperplasia (BPH)." | 5.19 | Is the double dose alpha-blocker treatment superior than the single dose in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia? ( Kara, O; Yazici, M, 2014) |
| "The aim of this study was to assess patient outcome after discontinuation of alfuzosin treatment in patients with benign prostatic hyperplasia (BPH)." | 5.17 | Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study. ( Chung, JH; Han, JH; Jo, JK; Kang, DH; Kim, TH; Lee, JW; Lee, JY; Lee, KS; Lee, SH; Lee, SW, 2013) |
| " We compared the efficacy of alfuzosin 10 mg alone or in combination with sildenafil 50 mg in the treatment of LUTS due to benign prostatic hyperplasia." | 5.16 | Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms. ( Akyüz, M; Güneş, M; Kalkan, S; Karaman, MI; Koca, O; Öztürk, Mİ, 2012) |
| "To evaluate the efficacy of alfuzosin treatment on voiding and storage in patients with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) with respect to bladder outlet obstruction and contractility." | 5.15 | The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility. ( Cho, JS; Choo, MS; Han, JY; Kim, JC; Lee, KS; Lee, YS; Song, K, 2011) |
| "The aim of this study was to compare the efficacy and safety of alfuzosin (Alf) and tamsulosin (Tam) in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)." | 5.15 | Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia. ( Atahan, Ö; Budak, YU; Karadağ, E; Öner, S, 2011) |
| "To compare the efficacy of Alfuzosin XL 10 mg once daily for the acute management of acute urinary retention (AUR) with placebo in patients with benign prostatic hyperplasia (BPH) and to determine the predictors that impact this." | 5.14 | Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. ( Consigliere, D; Li, MK; Macalalag, M; Tibung, MJ; Tiong, HY, 2009) |
| "To determine the effect of alfuzosin on sexual function by using the Male Sexual Health Questionnaire (MSHQ) in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)." | 5.14 | An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia. ( Cheon, J; Chung, BH; Chung, MK; Kim, MK; Kim, SW; Lee, JY; Lee, KS; Lee, SW; Park, JK; Park, K, 2010) |
| "To evaluate the effect of alfuzosin 10 mg once daily administered for 2 years on progression events in men with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH)." | 5.12 | Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. ( Roehrborn, CG, 2006) |
| "To determine the efficacy and safety of the selective alpha(1)-blocker alfuzosin in men with lower urinary tract symptoms (LUTS) and painful ejaculation, compared with those with LUTS only, as painful ejaculation is one of the most prevalent, differentiating and bothersome symptoms in men with chronic prostatitis/chronic pelvic pain syndrome." | 5.12 | The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. ( Elhilali, M; Emberton, M; Nickel, JC; Vallancien, G, 2006) |
| "This randomized, double-blind, placebo-controlled study was conducted to investigate whether alfuzosin 10 mg once daily improves the maximum flow rate (Q(max)) and lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH) after 1 week and 1 month of treatment." | 5.12 | Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. ( Resnick, MI; Roehrborn, CG, 2007) |
| "This pilot study was undertaken to assess the efficacy and safety of the alpha(1)-blocker alfuzosin 10mg once daily (OD), the PDE-5 inhibitor sildenafil 25mg OD, and the combination of both on lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and erectile dysfunction (ED)." | 5.12 | Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. ( Gonzalez, RR; Kaplan, SA; Te, AE, 2007) |
| "To study the impact of alfuzosin 10 mg once daily (OD) on the outcome of a trial without catheter (TWOC) after a first episode of acute urinary retention (AUR) related to benign prostatic hyperplasia (BPH) and the subsequent management of BPH in these patients." | 5.11 | Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. ( Hargreave, TB; McNeill, SA; Roehrborn, CG, 2005) |
| "A new patented prolonged release formulation of the alpha1-adrenoceptor antagonist alfuzosin has been developed for once-daily (OD) administration in benign prostatic hyperplasia (BPH)." | 5.10 | Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects. ( Ahtoy, P; Chrétien, P; Delfolie, A; Dupain, T; Rauch, C; Rouchouse, A, 2002) |
| "The blood and prostatic concentrations of alfuzosin were determined in patients with benign prostatic hyperplasia (BPH)." | 5.10 | Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. ( Bressolle, F; Costa, P; Delmas, V; Mottet, N; Robert, M, 2003) |
| "To examine the efficacy and safety of a once-daily formulation of alfuzosin in a pooled analysis of three parallel, randomized, double-blind, placebo-controlled 3-month studies of patients with lower urinary tract symptoms (LUTS) consistent with clinical benign prostatic hyperplasia." | 5.10 | Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. ( Nordling, J; Roehrborn, CG; Van Kerrebroeck, P, 2003) |
| "Together, our findings suggest that alfuzosin OD exhibits a urodynamically measurable effect on bladder outlet obstruction due to benign prostatic hyperplasia in men with lower urinary tract symptoms within hours of the first administration." | 5.10 | First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. ( Forrest, J; Gittelman, M; Jacobs, S; Kim, D; Marks, LS; Roehrborn, CG, 2003) |
| ") prolonged-release formulation of the clinically uroselective alpha1-blocker, alfuzosin, in patients with symptomatic benign prostatic hyperplasia (BPH)." | 5.10 | Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. ( Jardin, A; Laval, KU; van Cangh, P; van Kerrebroec, P, 2002) |
| "To establish whether the administration of sustained-release (SR) alfuzosin improves the outcome of a trial without catheter (TWOC) after an episode of acute urinary retention." | 5.09 | Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled. ( Daruwala, PD; Hargreave, TB; McNeill, SA; Mitchell, ID; Shearer, MG, 1999) |
| "As we have previously published 4 articles reporting the treatment of 7,093 clinical benign prostatic hyperplasia (BPH) patients treated with alfuzosin in a 3-month open-labelled study which was subsequently extended to 12, 24, and 36 months, the objective of this article is to provide additional data on dropouts, acute urinary retention (AUR), progression to surgery, and safety under the natural conditions of general practice, paying special attention to the predictive factors." | 5.09 | History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. ( Comet, D; Grange, JC; Lukacs, B; McCarthy, C, 2000) |
| "To assess the efficacy and safety of a new prolonged release formulation of the uroselective alpha(1)-blocker alfuzosin for a once-daily dosing regimen in patients with lower urinary tract symptoms (LUTS) suggestive of symptomatic benign prostatic hyperplasia (BPH)." | 5.09 | Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. ( Jardin, A; Laval, KU; van Cangh, P; van Kerrebroeck, P, 2000) |
| "This general practitioner-run study assess the security as well as the efficacy and impact on health-related quality of life of a sustained-release (SR) form of alfuzosin in Spanish patients suffering from lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)." | 5.09 | Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice. ( Alfaro, V; Badiella, L; Fernández-Hernando, N; Guil, M; Sánchez-Chapado, M, 2000) |
| "To assess the effect of the age of patients with benign prostatic hyperplasia (BPH) on the clinical uroselectivity of alfuzosin during general medical practice." | 5.09 | The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ( Alfaro, V; Badiella, LI; Fernández-Hernando, N; Guil, M; Sánchez-Chapado, M, 2000) |
| "To assess the efficacy and safety, and determine the optimal dosage, of a once-daily (OD) formulation of the clinically uroselective alpha(1)-blocker, alfuzosin, in patients with lower urinary tract symptoms and symptomatic benign prostatic hyperplasia." | 5.09 | Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. ( Roehrborn, CG, 2001) |
| "To assess the symptomatic outcome following transurethral prostatectomy (TURP), alpha-blockade and placebo treatment in uncomplicated benign prostatic hyperplasia (BPH), 260 patients were evaluated with the recently formulated Danish Prostatic Symptom Score (DAN-PSS-1) system: 205 were randomized to either the selective alpha-blocker alfuzosin or placebo and 55 underwent TURP." | 5.08 | Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group. ( Flyger, H; Hansen, BJ; Mensink, HJ; Meyhoff, HH; Mortensen, S, 1996) |
| "To investigate in men with benign prostatic hyperplasia (BPH) treated in the general practitioner setting (1) the magnitude and durability of symptom score improvement with alfuzosin; (2) the effect on patients perceived health-related quality of life (HRQL) and sexuality, (3) adverse outcomes and treatment failure; and (4) progression to acute urinary retention and prostate surgery." | 5.08 | Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. ( Jardin, A; Leplège, A; Lukacs, B; Thibault, P, 1996) |
| "To assess the efficacy and safety of a sustained-release (SR) formulation of alfuzosin, a selective alpha(1)-blocker, in patients with symptomatic benign prostatic hyperplasia (BPH)." | 5.08 | Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. ( Buzelin, JM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Roth, S, 1997) |
| "Two placebo-controlled studies involving 588 patients (292 receiving SR alfuzosin 5 mg twice daily and 296 a placebo) were pooled; 51% of the patients were > or = 65 years of age and 43% had associated cardiovascular disease including hypertension and/or were receiving concomitant antihypertensive drugs." | 5.08 | Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. ( Buzelin, JM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Roth, S; Santoni, JP, 1997) |
| "The objective of this double-blind, placebo-controlled urodynamic pressure/flow study was to assess the efficacy of short-term treatment with the alpha 1-blocker alfuzosin in outflow obstruction of patients with symptomatic benign prostatic hyperplasia (BPH)." | 5.08 | Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. ( Casadei, G; Colombo, R; Di Silverio, F; Giberti, C; Martorana, G; Pacifico, P; Rigatti, P; von Heland, M, 1997) |
| "To compare the efficacy and tolerability of the alpha 1 A-subtype selective drug tamsulosin with the nonsubtype-selective agent alfuzosin in the treatment of patients with lower urinary tract symptoms (LUTS) suggestive of bladder outlet obstruction (BOO), often termed symptomatic benign prostatic hyperplasia (BPH)." | 5.08 | Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. ( Buzelin, JM; Fonteyne, E; Khan, A; Kontturi, M; Witjes, WP, 1997) |
| "Alfuzosin, a selective alpha 1-adrenoceptor antagonist which is effective in the symptomatic treatment of benign prostatic hyperplasia (BPH), was compared with prazosin, another drug commonly used for the same purpose." | 5.07 | Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. ( Blondin, P; Buzelin, JM; Hebert, M, 1993) |
| "In order to assess the efficacy and safety of alfuzosin, a selective alpha-1 receptor antagonist, 205 patients with Benign Prostatic Hyperplasia (BPH) were randomly assigned in a double-blind, placebo-controlled manner, to receive either alfuzosin 2." | 5.07 | Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group. ( Hansen, BJ; Mensink, HJ; Meyhoff, HH; Nordling, J; Walter, S, 1994) |
| "To address the long-term results of alfuzosin, an alpha 1-antagonist, in patients with benign prostatic hyperplasia (BPH)." | 5.07 | Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. ( Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A; Stalla-Bourdillon, A, 1994) |
| "The effects of alfuzosin, a potent alpha 1-blocker, were assessed in patients with benign prostatic hyperplasia, in a double-blind, multicenter, placebo-controlled, cross-over study." | 5.07 | Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group. ( De Sy, W; Santoni, JP; Schulman, CC; Tomas, M; Vandendris, M, 1994) |
| "In order to assess the efficacy and safety of alfuzosin, an alpha-1 blocker, in symptomatic patients with benign prostatic hyperplasia (BPH), 131 patients who had completed a 6-month placebo-controlled trial conducted on parallel groups entered a 12-month open study; 122 patients were treated with alfuzosin for 12 months and 56 patients for 18 months." | 5.07 | Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group. ( Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A, 1993) |
| " Search terms included benign prostatic hyperplasia, alfuzosin, treatment, alpha(1)-adrenergic receptor blocker, long-term, followup, lower urinary tract symptoms, complications or adverse events, sexual, retention and cardiovascular." | 4.83 | Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. ( McVary, KT, 2006) |
| "alpha(1)-Adrenoceptor antagonists such as alfuzosin, doxazosin, tamsulosin and terazosin are first-line agents for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH), but are only second-line agents (doxazosin and terazosin only) for the treatment of arterial hypertension." | 4.83 | Effects of alpha(1)-adrenoceptor antagonists on male sexual function. ( de la Rosette, JJ; Michel, MC; van Dijk, MM, 2006) |
| "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of alfuzosin hydrochloride in the treatment of benign prostatic hyperplasia (BPH) are discussed." | 4.82 | Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. ( Lee, M, 2003) |
| "Extended-release (ER) alfuzosin hydrochloride is the most recently approved alpha-adrenergic receptor antagonist (AARA) for the management of symptomatic benign prostatic hyperplasia (BPH)." | 4.82 | Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. ( Guay, DR, 2004) |
| "To evaluate the efficacy and adverse effects of alfuzosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH)." | 4.82 | Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. ( MacDonald, R; Wilt, TJ, 2005) |
| "A pooled analysis was conducted in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia to examine the relationship between the postvoid residual urine (PVR) volume and various clinical characteristics and to assess the effect of alfuzosin, a clinically uroselective alpha(1)-blocker, on PVR volume and any other associated outcome." | 4.81 | Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. ( Geffriaud-Ricouard, C; Hargreave, TB; McNeill, SA; Roehrborn, CG; Santoni, J, 2001) |
| "The efficacy of alfuzosin in improving lower urinary tract symptoms and relieving bladder outlet obstruction has been demonstrated in numerous short- and long-term placebo-controlled studies and large-scale open studies, involving over 16,000 patients with symptomatic benign prostatic hyperplasia (BPH)." | 4.80 | Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia. ( Kirby, RS, 1998) |
| "To study the efficiency of using alfuzosin 10 mg (Alfuprost MR, SUN Pharma) in routine clinical practice in order to predict its feasibility for treating acute urinary retention." | 3.96 | [The use of alfuzosin in the treatment of patients with acute urinary retention]. ( Ergakov, DV; Martov, AG, 2020) |
| "Alfuzosin and tamsulosin are recently co-administrated with vardenafil to treat symptoms of benign prostatic hyperplasia and erectile dysfunction." | 3.91 | Simultaneous HPLC determination of alfuzosin, tamsulosin and vardenafil in human plasma and pharmaceutical formulations using time programmed fluorescence detection. ( Belal, F; Borg, H; Fathy, M; Walash, MI; Zayed, S, 2019) |
| "To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >8 (range of scores, 0-35), and sexual attempts at least once per month were enrolled." | 3.78 | Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia. ( Chang, HC; Chen, CS; Chen, WH; Chiang, PH; Chu, SH; Hwang, TI; Lee, LM; Lin, MS; Yeh, SD, 2012) |
| "We report on 1 case of alfuzosin induced thrombocytopenia after treatment for benign prostatic hyperplasia." | 3.76 | Alfuzosin induced thrombocytopenia after treatment for benign prostatic hyperplasia. ( Güner, E; Güner, S; Mutlu, B; Taşçi, AI, 2010) |
| "Assess safety and efficacy of 10-mg prolonged-release alfuzosin (Xatral XL) in benign prostatic hyperplasia (BPH) patients with lower urinary tract symptoms (LUTS)." | 3.75 | Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ( Chodchoy, V; Kongkanand, A; Lojanapiwat, B; Pumpaisanchai, S; Ratana-Olarn, K; Sae-Tang, P; Taweemonkongsap, T, 2009) |
| "To compare the incidence of intraoperative floppy-iris syndrome (IFIS) in men exposed to tamsulosin and men exposed to alfuzosin and evaluate the effect of IFIS on the complication rate of cataract surgery." | 3.74 | Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin. ( Blouin, J; Blouin, MC; Dragomir, A; Lapointe, A; Perreault, S, 2007) |
| "The construction and characterization of potentiometric membrane electrodes are described for the quantification of alfuzosin, a drug used in a mono- and combined therapy of benign prostatic hyperplasia (BPH)." | 3.74 | Potentiometric sensors enabling fast screening of the benign prostatic hyperplasia drug alfuzosin in pharmaceuticals, urine and serum. ( Gupta, B; Gupta, VK; Singh, AK, 2007) |
| "To assess the 3-year efficacy and safety of the selective alpha(1)-blocker alfuzosin at 10 mg once daily in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in 'real-life practice'." | 3.74 | Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ, 2008) |
| "To assess the predictors of acute urinary retention (AUR) and/or surgery related to benign prostatic hyperplasia (BPH) in 3514 men complaining of lower urinary tract symptoms and treated for 6 months with the selective alpha1-blocker alfuzosin at 10 mg once daily." | 3.73 | Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, J, 2005) |
| "To calculate the economic consequences of using alfuzosin 10 mg once daily for managing acute urinary retention (AUR) related to benign prostatic hyperplasia (BPH)." | 3.73 | The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis. ( Annemans, L; Cleemput, I; Hargreave, T; Lamotte, M; McNeill, A, 2005) |
| "We analyzed the influence of treatment response on the risk of acute urinary retention and benign prostatic hyperplasia related surgery in 5,792 men complaining of lower urinary tract symptoms who were treated for 6 months with the selective alpha1-blocker alfuzosin at 10 mg once daily." | 3.73 | Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. ( Alcaraz, A; Elhilali, M; Emberton, M; Lukacs, B; Matzkin, H; Vallancien, G, 2006) |
| "The aim of our study was to evaluate the symptomatic and urodynamic changes after 1-5 years of treatment with alfuzosin in patients with benign prostatic hyperplasia." | 3.72 | Clinical and pressure-flow changes after long-term treatment with alfuzosin SR. ( De Nunzio, C; Franco, G; Iori, F; Laurenti, C; Leonardo, C; Minardi, V, 2003) |
| "To determine the effectiveness of alfuzosin on symptom reduction, patients' perceived health-related quality of life (HRQL) improvement, adverse outcomes, treatment failure, and progression to acute urinary retention and prostate surgery in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH) in a 1-year prospective, open-labeled study." | 3.70 | One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice. ( Comet, D; Grange, JC; Lukacs, B, 2000) |
| "40 patients with benign prostatic hyperplasia (BPH) were treated with the alpha-blocker alfuzosin which was administered per os twice a day in a dose 5 mg." | 3.69 | [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin]. ( Matushevskiĭ, IA; Mazo, EB; Nikitin, IuIu, 1997) |
| "The adrenergic alpha-1 and -2 adrenoceptors in six human hypertrophied prostatic adenomas were measured in the saturation experiment using 3H-prazosin and 3H-yohimbine." | 3.68 | [Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas]. ( Kondo, S; Morita, T, 1992) |
| "Patients with symptomatic benign prostatic hyperplasia and cataracts requiring a uroselective α1-antagonist may consider trying alfuzosin first." | 2.79 | Prospective masked comparison of intraoperative floppy iris syndrome severity with tamsulosin versus alfuzosin. ( Campbell, JR; Chang, DF; Colin, J; Schweitzer, C, 2014) |
| "With tamsulosin treatment, both mesopic and scotopic PD decreased, respectively, from 3." | 2.73 | The effects of two systemic alpha1-adrenergic blockers on pupil diameter: a prospective randomized single-blind study. ( Adibelli, FM; Akova, YA; Altan-Yaycioglu, R; Gul, U; Pelit, A; Yaycioglu, O, 2007) |
| "The aetiology of AUR was benign prostatic hyperplasia (BPH) in 29 patients and constipation in the remaining 2 patients." | 2.72 | A prospective pilot study to validate the management protocol for patients presenting with acute urinary retention: a community-based, nonhospitalised protocol. ( Byrne, DJ; Goodman, CM; Gopi, SS; Robertson, A, 2006) |
| "Doxazosin and alfuzosin were both well tolerated, with most all-cause adverse events reported as mild or moderate." | 2.71 | Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. ( de Reijke, TM; Klarskov, P, 2004) |
| "Treatment with alfuzosin 10 mg significantly improved urinary symptoms and Qmax compared with placebo and was well tolerated." | 2.71 | Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. ( Nordling, J, 2005) |
| "Alfuzosin 10 mg OD is an effective treatment for symptomatic BPH for at least 12 months, with a better cardiovascular safety profile than the immediate release formulation." | 2.70 | The efficacy and safety of a new once-a-day formulation of an alpha-blocker. ( Van Kerrebroeck, PE, 2001) |
| "Alfuzosin was well tolerated: the quantitative and qualitative distribution of adverse events (AEs) was similar to that previously observed in placebo-controlled studies." | 2.69 | Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice. ( Comet, D; Grange, JC; Lukacs, B; McCarthy, C, 1998) |
| " To date, the role of varying dosing regimens in responding patients has not been well studied." | 2.69 | Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms. ( Cologna, A; Kaplan, SA; Kohn, IJ; Martins, AC; Reis, RB; Suaid, HJ; Te, AE, 1998) |
| "Alfuzosin was well tolerated: the qualitative and quantitative distribution of adverse effects was identical to that previously observed in placebo-controlled trials (vertigo-dizziness: 2." | 2.69 | [Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years wi alfuzosin in general practice. BPH Group in General Practice]. ( Comet, D; Grange, JC; Lukacs, B; Mc Carthy, C, 1999) |
| "01)." | 2.69 | Safety, efficacy and impact on Patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. The Italian Alfuzosin Co-Operative Group. ( , 2000) |
| "Alfuzosin was prescribed at the recommended dose of 2." | 2.68 | Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. ( Blondin, P; Du Boys, B; Grippon, P; Lassale, C; Lukacs, B; MacCarthy, C, 1996) |
| "Alfuzosina has a specific antagonist effect on the alfa-1-adrenergic post-junctional receptor posed at urethral laeve musculature, prostatic capsule and vesical trgonum." | 2.67 | [Assessment of the effects of alfuzosin on miction with dynamic echography]. ( Gentili, G; Mautone, A; Milani, M; Tucci, G, 1994) |
| "Alfuzosin was demonstrated to be effective with respect to out-flow obstructive symptoms (quality of the stream, hesitancy, sensation of incomplete emptying of the bladder) and other functional symptoms (diurnal frequency and nocturia)." | 2.66 | [Efficacy of an alpha-blocker, alfuzosin, on urinary disorders in men with prostatic adenoma. Intermediate results of a European multicenter study]. ( Jardin, A, 1988) |
| "Silodosin is a novel, more selective alpha-blocker, which is specific to the lower urinary tract and may have fewer side effects than other alpha-blockers." | 2.55 | Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. ( Dahm, P; Jung, JH; Kim, J; Kim, MH; MacDonald, R; Reddy, B, 2017) |
| " α(1) Blockers generally lead to more adverse effects compared with placebo, and those caused by terazosin were more frequent than others." | 2.49 | The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. ( Liu, Y; Mao, C; Qin, X; Yang, K; Yang, Z; Yuan, J, 2013) |
| "Alfuzosin is a uroselective alpha(1)-blocker that relaxes the smooth muscle of the bladder neck and prostate gland to alleviate BPH symptoms." | 2.43 | Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia. ( Kuritzky, L; Rosenberg, MT; Sadovsky, R, 2006) |
| "The progression of benign prostatic hyperplasia (BPH) can be defined as a deterioration of clinical variables such as lower urinary tract symptoms (LUTS), health-related quality of life and peak flow rate, increased prostate size, or unfavourable outcomes such as acute urinary retention (AUR) and BPH-related surgery." | 2.43 | The natural history of benign prostatic hyperplasia. ( Fitzpatrick, JM, 2006) |
| "Medical treatment for benign prostatic hyperplasia is reviewed by the author." | 2.42 | [Pharmacologic treatment of benign prostatic hyperplasia]. ( Romics, I, 2003) |
| " The confirmed efficacy, proven bioavailability and good cardiovascular safety profile support the use of this drug for the management of lower urinary tract symptoms secondary to benign prostate hyperplasia (BPH)." | 2.42 | Alfuzosin for the management of benign prostate hyperplasia. ( Lowe, FC; Weiner, DM, 2003) |
| "Tamsulosin has selectivity for the a alpha(1) and alpha(1d) receptor subtypes." | 2.42 | Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. ( Lowe, FC, 2004) |
| "As alfuzosin has been shown to reduce PVR, this factor may help prevent recurrent retention following TWOC." | 2.41 | Does acute urinary retention respond to alpha-blockers alone? ( McNeill, SA, 2001) |
| " The most frequently reported adverse event potentially related to alpha blockade was dizziness, which occurred in 5." | 2.41 | Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. ( Roehrborn, CG, 2001) |
| " No dosage titration is required." | 2.41 | Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. ( McKeage, K; Plosker, GL, 2002) |
| ") formulation of alfuzosin has recently been developed in order to improve the convenience of dosing and to provide optimal pharmacokinetic coverage over a 24-h period." | 2.41 | Alfuzosin: a clinically uroselective alpha1-blocker. ( Höfner, K; Jonas, U, 2002) |
| "dizziness and orthostatic hypotension)." | 2.40 | A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. ( Djavan, B; Marberger, M, 1999) |
| " A limited range of clinical studies have shown oral alfuzosin to be more effective than placebo (in studies of < or = 6 months duration), to have sustained effects on long term administration (< or = 30 months), and to be comparable with the alpha 1-adrenoceptor antagonist prazosin, in the symptomatic treatment of benign prostatic hyperplasia." | 2.38 | Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. ( Fitton, A; McTavish, D; Wilde, MI, 1993) |
| " The follow-up included 3 visits: visit of inclusion in the program of patients with a previously prescribed drug of Alfuprost MR in a dosage of 10 mg once a day (visit "0"), visit 1 at 30 days (+/-5 days) later, and visit 2 at 90 days (+/-5 days) after inclusion in the study." | 1.72 | [The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)]. ( Bernikov, AN; Loran, OB; Pushkar, DY, 2022) |
| "The delayed presentation of spinal cord ischemia was precipitated by commencement of alpha-blockers for benign prostatic hyperplasia." | 1.51 | Successful reversal of isolated delayed spinal cord ischemia following endovascular abdominal aneurysm repair. ( Al-Jarrah, M; Al-Omari, MH; Aljarrah, Q; Alzoubi, A; Elheis, M; Jamal, A, 2019) |
| "Incidence of benign prostatic hyperplasia (BPH), one of the most common conditions affecting adult men, increases dramatically after the age of 50." | 1.42 | [Impact of alfuzosin 10 mg once daily on quality of life in Tunisian patients with lower urinary symptoms suggestive of benign prostatic hyperplasia]. ( Adbi, H; Ben Raies, N; Ben Rhouma, S; Binous, MY; H'sairi, M; Horchani, A; Mosbah, AT; Nouira, Y, 2015) |
| "Secondary outcomes of hypotension and head trauma were also significantly increased in the exposed cohort (odds ratios 1." | 1.42 | The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study. ( Dixon, S; Fraser, LA; Hayward, J; Hwang, YJ; McArthur, E; Ordon, M; Welk, B, 2015) |
| "The standard gold care medications for benign prostatic hyperplasia (BPH) are the alpha-1-adrenergic antagonists, they are an effective medications and are generally well tolerated." | 1.40 | Alpha-1 adrenergic antagonists induced severe rhinitis in patients with benign prostatic hyperplasia. ( Hassoun, G; Kedem, E; Nassar, L; Shahar, E, 2014) |
| "Since trial results for benign prostatic hyperplasia phytotherapeutic agents are inconsistent, they may also be contaminated." | 1.36 | Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors. ( Adomat, H; Elterman, DS; Fleshner, N; Guns, E; Hersey, K; Lawrentschuk, N; Wood, CA, 2010) |
| "Doxazosin GITS treatment resulted in optimal management of BP within the normal range, especially in pharmacologically or physiologically hypertensive patients." | 1.36 | Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension. ( Chung, BH; Lee, SH; Mah, SY; Park, KK, 2010) |
| "Forty males with benign prostatic hyperplasia (BPH) applying to the Department of Urology with lower urinary tract symptoms (LUTS) were enrolled in the study consecutively." | 1.35 | Comparing the therapeutic outcome of different alpha-blocker treatments for BPH in the same individuals. ( Adayener, C; Akyol, I; Ates, F; Iseri, C; Senkul, T; Yilmaz, O, 2008) |
| "A novel slow release formulation of alfuzosin should improve compliance by reducing dosing to one 10 mg tablet per day." | 1.33 | Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin. ( Casey, R; Elhilali, M; Kuzmarov, I; Nickel, JC; Saad, F; Valiquette, L, 2005) |
| "Alfuzosin 10 mg was well tolerated; the most common adverse event related to vasodilatation was dizziness/postural dizziness (3." | 1.33 | Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ, 2006) |
| " Just 16 patients (3%) developed adverse events; measures undertaken were to modify the dosage or to interrupt the treatment (2 cases)." | 1.31 | [Prostatic benign hypertrophy: review of effectiveness, tolerance, and impact on quality of life of prolonged treatment with alfuzosin]. ( Ausín, I; Barajas, R; Gabriel, R; Vela Navarrete, R, 2000) |
| "Tamsulosin has a markedly lower re-treatment percentage than alfuzosin and terazosin." | 1.31 | Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. ( de la Rosette, JJ; Floratos, DL; Kiemeney, LA; Kortmann, BB; Rossi, C; Sonke, GS, 2002) |
| "To construct and validate a short-form benign prostatic hypertrophy (BPH) health-related quality-of-life (HRQL) questionnaire which is more practical in use and as informative as the 20-item visual analogue scale questionnaire (QOL20) previously validated in French." | 1.30 | Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice. ( Comet, D; Grange, JC; Lukacs, B; Thibault, P, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.08) | 18.7374 |
| 1990's | 52 (27.96) | 18.2507 |
| 2000's | 92 (49.46) | 29.6817 |
| 2010's | 37 (19.89) | 24.3611 |
| 2020's | 3 (1.61) | 2.80 |
| Authors | Studies |
|---|---|
| Kenny, B | 1 |
| Ballard, S | 1 |
| Blagg, J | 1 |
| Fox, D | 1 |
| Meyer, MD | 2 |
| Altenbach, RJ | 2 |
| Basha, FZ | 2 |
| Carroll, WA | 2 |
| Condon, S | 1 |
| Elmore, SW | 1 |
| Kerwin, JF | 2 |
| Sippy, KB | 2 |
| Tietje, K | 2 |
| Wendt, MD | 2 |
| Hancock, AA | 2 |
| Brune, ME | 2 |
| Buckner, SA | 2 |
| Drizin, I | 2 |
| Bai, H | 1 |
| Lebold, SA | 1 |
| Lee, E | 1 |
| Pratt, JK | 1 |
| Pushkar, DY | 1 |
| Loran, OB | 1 |
| Bernikov, AN | 1 |
| Ohyama, K | 1 |
| Hori, Y | 1 |
| Sugiura, M | 1 |
| Martov, AG | 1 |
| Ergakov, DV | 1 |
| Minh, TD | 1 |
| Thanh Ha, TN | 1 |
| Duy, TN | 1 |
| Hoang, NN | 1 |
| PhamTien, D | 1 |
| Thai, HP | 1 |
| Thi, HN | 1 |
| Thi Lan, PD | 1 |
| Quoc, BP | 1 |
| Ivkin, DY | 1 |
| Povydysh, MN | 1 |
| Cong, BN | 1 |
| Krasnova, MV | 1 |
| Dogan, M | 1 |
| Kutluksaman, B | 1 |
| Keles, I | 1 |
| Karalar, M | 1 |
| Halat, AO | 1 |
| Jung, JH | 1 |
| Kim, J | 1 |
| MacDonald, R | 2 |
| Reddy, B | 1 |
| Kim, MH | 1 |
| Dahm, P | 1 |
| Walash, MI | 1 |
| Belal, F | 1 |
| Fathy, M | 1 |
| Zayed, S | 1 |
| Borg, H | 1 |
| Aljarrah, Q | 1 |
| Al-Omari, MH | 1 |
| Elheis, M | 1 |
| Al-Jarrah, M | 1 |
| Jamal, A | 1 |
| Alzoubi, A | 1 |
| Praus, F | 1 |
| Miernik, A | 1 |
| Chung, JH | 1 |
| Lee, JY | 2 |
| Kang, DH | 1 |
| Jo, JK | 1 |
| Lee, JW | 2 |
| Lee, SH | 2 |
| Lee, KS | 4 |
| Kim, TH | 1 |
| Han, JH | 1 |
| Lee, SW | 3 |
| Maldonado-Ávila, M | 1 |
| Manzanilla-García, HA | 1 |
| Sierra-Ramírez, JA | 1 |
| Carrillo-Ruiz, JD | 1 |
| González-Valle, JC | 1 |
| Rosas-Nava, E | 1 |
| Guzman-Esquivel, J | 1 |
| Labra-Salgado, IR | 1 |
| Chang, DF | 1 |
| Campbell, JR | 1 |
| Colin, J | 1 |
| Schweitzer, C | 1 |
| Shahar, E | 1 |
| Nassar, L | 1 |
| Kedem, E | 1 |
| Hassoun, G | 1 |
| Kara, O | 1 |
| Yazici, M | 1 |
| Bulut, S | 1 |
| Ozden, C | 1 |
| Aktas, BK | 1 |
| Deren, T | 1 |
| Tagci, S | 1 |
| Gokkaya, CS | 1 |
| Baykam, MM | 1 |
| Memis, A | 1 |
| Salah Azab, S | 1 |
| Elsheikh, MG | 1 |
| Umul, M | 1 |
| Altay, AB | 1 |
| Bademkiran, F | 1 |
| Turna, B | 1 |
| Semerci, MB | 1 |
| Apaydin, E | 1 |
| Cikili, N | 1 |
| Zhang, LT | 1 |
| Park, K | 2 |
| Chung, WS | 1 |
| Kim, SW | 2 |
| Hyun, JS | 1 |
| Moon, DG | 1 |
| Yang, SK | 1 |
| Ryu, JK | 1 |
| Yang, DY | 1 |
| Moon, KH | 1 |
| Min, KS | 1 |
| Park, JK | 2 |
| Barkin, J | 1 |
| Diles, D | 1 |
| Franks, B | 1 |
| Berner, T | 1 |
| Ben Rhouma, S | 1 |
| H'sairi, M | 1 |
| Adbi, H | 1 |
| Binous, MY | 1 |
| Nouira, Y | 1 |
| Ben Raies, N | 1 |
| Mosbah, AT | 1 |
| Horchani, A | 1 |
| Welk, B | 1 |
| McArthur, E | 1 |
| Fraser, LA | 1 |
| Hayward, J | 1 |
| Dixon, S | 1 |
| Hwang, YJ | 1 |
| Ordon, M | 1 |
| Armarnik, S | 1 |
| Mimouni, M | 1 |
| Rosen, E | 1 |
| Assia, EI | 1 |
| Segev, F | 1 |
| Minutoli, L | 1 |
| Rinaldi, M | 1 |
| Marini, H | 1 |
| Irrera, N | 1 |
| Crea, G | 1 |
| Lorenzini, C | 1 |
| Puzzolo, D | 1 |
| Valenti, A | 1 |
| Pisani, A | 1 |
| Adamo, EB | 1 |
| Altavilla, D | 1 |
| Squadrito, F | 1 |
| Micali, A | 1 |
| Arikan, G | 1 |
| Demir, O | 1 |
| Yaman, A | 1 |
| Bozkurt, O | 1 |
| Saatci, AO | 1 |
| Durak, I | 1 |
| Esen, A | 1 |
| Mamalis, N | 1 |
| Bar-Yosef, Y | 1 |
| Mabjeesh, NJ | 1 |
| Laufer, M | 1 |
| Neulander, EZ | 1 |
| Kaver, I | 1 |
| Matzkin, H | 5 |
| Roehrborn, CG | 10 |
| Rosen, RC | 1 |
| Wiygul, J | 1 |
| Babayan, RK | 1 |
| Roumeguère, T | 1 |
| Zouaoui Boudjeltia, K | 1 |
| Hauzeur, C | 1 |
| Schulman, C | 1 |
| Vanhaeverbeek, M | 1 |
| Wespes, E | 1 |
| Kongkanand, A | 1 |
| Chodchoy, V | 1 |
| Lojanapiwat, B | 2 |
| Pumpaisanchai, S | 1 |
| Ratana-Olarn, K | 1 |
| Sae-Tang, P | 1 |
| Taweemonkongsap, T | 1 |
| Tiong, HY | 1 |
| Tibung, MJ | 1 |
| Macalalag, M | 1 |
| Li, MK | 1 |
| Consigliere, D | 1 |
| Kim, MK | 1 |
| Cheon, J | 1 |
| Chung, MK | 1 |
| Chung, BH | 2 |
| Leungwattanakij, S | 1 |
| Watanachote, D | 1 |
| Noppakulsatit, P | 1 |
| Petchpaibuol, T | 1 |
| Choeypunt, N | 1 |
| Tongbai, T | 1 |
| Wanamkang, T | 1 |
| Permpongkosol, S | 2 |
| Tantiwong, A | 1 |
| Pripatnanont, C | 1 |
| Akarasakul, D | 1 |
| Kongwiwatanakul, S | 1 |
| Chotikawanich, E | 1 |
| Elterman, DS | 1 |
| Lawrentschuk, N | 1 |
| Guns, E | 1 |
| Hersey, K | 1 |
| Adomat, H | 1 |
| Wood, CA | 1 |
| Fleshner, N | 1 |
| Park, KK | 1 |
| Mah, SY | 1 |
| Lee, YS | 2 |
| Lee, HN | 1 |
| Han, JY | 2 |
| Choo, MS | 2 |
| Song, K | 1 |
| Kim, JC | 1 |
| Cho, JS | 1 |
| Alan, C | 1 |
| Kırılmaz, B | 1 |
| Koçoğlu, H | 1 |
| Ersay, AR | 1 |
| Ertung, Y | 1 |
| Eren, AE | 1 |
| Güner, S | 1 |
| Mutlu, B | 1 |
| Güner, E | 1 |
| Taşçi, AI | 1 |
| Karadağ, E | 1 |
| Öner, S | 1 |
| Budak, YU | 1 |
| Atahan, Ö | 1 |
| Giannakopoulos, XK | 1 |
| Giotis, C | 1 |
| Karkabounas, SCh | 1 |
| Verginadis, II | 1 |
| Simos, YV | 1 |
| Peschos, D | 1 |
| Evangelou, AM | 1 |
| Krilad-O-Larn, S | 1 |
| Ratana-O-Larn, K | 1 |
| Öztürk, Mİ | 1 |
| Kalkan, S | 1 |
| Koca, O | 1 |
| Güneş, M | 1 |
| Akyüz, M | 1 |
| Karaman, MI | 1 |
| Sherman, JJ | 1 |
| Welch, RW | 1 |
| Hill, TM | 1 |
| McEwen, C | 1 |
| Theodossiadis, PG | 1 |
| Achtsidis, V | 1 |
| Theodoropoulou, S | 1 |
| Tentolouris, N | 1 |
| Komninos, C | 1 |
| Fountas, KN | 1 |
| Hwang, TI | 1 |
| Chu, SH | 1 |
| Lin, MS | 1 |
| Chen, CS | 1 |
| Lee, LM | 1 |
| Chang, HC | 1 |
| Yeh, SD | 1 |
| Chen, WH | 1 |
| Chiang, PH | 1 |
| Lee, HJ | 1 |
| Yuan, J | 1 |
| Liu, Y | 1 |
| Yang, Z | 1 |
| Qin, X | 1 |
| Yang, K | 1 |
| Mao, C | 1 |
| Ahtoy, P | 1 |
| Chrétien, P | 1 |
| Dupain, T | 1 |
| Rauch, C | 1 |
| Rouchouse, A | 1 |
| Delfolie, A | 1 |
| Pool, JL | 1 |
| Kirby, RS | 2 |
| Başar, MM | 1 |
| Atan, A | 1 |
| Ozergin, O | 1 |
| Yildiz, M | 1 |
| Doherty, AP | 1 |
| Larson, TR | 1 |
| Palea, S | 1 |
| Barras, M | 1 |
| Mottet, N | 1 |
| Bressolle, F | 1 |
| Delmas, V | 1 |
| Robert, M | 1 |
| Costa, P | 1 |
| Borer, J | 1 |
| Armstrong, P | 1 |
| De Nunzio, C | 1 |
| Franco, G | 1 |
| Iori, F | 1 |
| Leonardo, C | 1 |
| Minardi, V | 1 |
| Laurenti, C | 1 |
| Van Kerrebroeck, P | 2 |
| Nordling, J | 6 |
| Lee, M | 1 |
| Romics, I | 1 |
| Weiner, DM | 1 |
| Lowe, FC | 2 |
| Marks, LS | 1 |
| Gittelman, M | 1 |
| Kim, D | 1 |
| Forrest, J | 1 |
| Jacobs, S | 1 |
| Wyllie, MG | 1 |
| Brown, GA | 1 |
| Sussman, DO | 1 |
| de Reijke, TM | 2 |
| Klarskov, P | 1 |
| Simon, HB | 1 |
| McNeill, AS | 2 |
| Rizvi, S | 1 |
| Byrne, DJ | 2 |
| Guay, DR | 1 |
| McNeill, SA | 4 |
| Hargreave, TB | 3 |
| Bozlu, M | 1 |
| Ulusoy, E | 1 |
| Cayan, S | 1 |
| Akbay, E | 2 |
| Görür, S | 1 |
| Emberton, M | 7 |
| Elhilali, M | 6 |
| Harving, N | 3 |
| van Moorselaar, J | 1 |
| Hartung, R | 3 |
| Alcaraz, A | 4 |
| Vallancien, G | 5 |
| Annemans, L | 1 |
| Cleemput, I | 1 |
| Lamotte, M | 1 |
| McNeill, A | 1 |
| Hargreave, T | 1 |
| Saad, F | 1 |
| Nickel, JC | 2 |
| Valiquette, L | 1 |
| Casey, R | 1 |
| Kuzmarov, I | 1 |
| Wilt, TJ | 1 |
| Egilmez, T | 1 |
| Pourbagher, MA | 1 |
| Guvel, S | 1 |
| Kilinc, F | 1 |
| Turunc, T | 1 |
| Ozkardes, H | 1 |
| McVary, KT | 1 |
| Irani, J | 1 |
| Armitage, JN | 1 |
| van Moorselaar, RJ | 2 |
| Kuritzky, L | 1 |
| Rosenberg, MT | 1 |
| Sadovsky, R | 1 |
| Settas, G | 1 |
| Fitt, AW | 1 |
| Fitzpatrick, JM | 1 |
| van Dijk, MM | 1 |
| de la Rosette, JJ | 4 |
| Michel, MC | 2 |
| Desgrandchamps, F | 1 |
| De La Taille, A | 1 |
| Doublet, JD | 1 |
| Elhilali, MM | 1 |
| O'Leary, MP | 1 |
| Wang, YS | 1 |
| Tay, YK | 1 |
| Kwok, C | 1 |
| Lukacs, B | 10 |
| Resnick, MI | 1 |
| Kaplan, SA | 2 |
| Gonzalez, RR | 1 |
| Te, AE | 2 |
| Sciarra, A | 1 |
| Altan-Yaycioglu, R | 1 |
| Yaycioglu, O | 1 |
| Gul, U | 1 |
| Pelit, A | 1 |
| Adibelli, FM | 1 |
| Akova, YA | 1 |
| Cheung, CM | 1 |
| Awan, MA | 1 |
| Peh, KK | 1 |
| Sandramouli, S | 1 |
| Mariappan, P | 1 |
| Brown, DJ | 1 |
| Blouin, MC | 1 |
| Blouin, J | 1 |
| Perreault, S | 1 |
| Lapointe, A | 1 |
| Dragomir, A | 1 |
| Gopi, SS | 1 |
| Goodman, CM | 1 |
| Robertson, A | 1 |
| Kim, SY | 1 |
| Kim, BH | 1 |
| Dong, SH | 1 |
| Kim, HJ | 1 |
| Chang, YW | 1 |
| Chang, R | 1 |
| Kim, YW | 1 |
| Gupta, VK | 1 |
| Singh, AK | 1 |
| Gupta, B | 1 |
| Senkul, T | 1 |
| Yilmaz, O | 1 |
| Iseri, C | 1 |
| Adayener, C | 1 |
| Akyol, I | 1 |
| Ates, F | 1 |
| Buzelin, JM | 5 |
| Hebert, M | 1 |
| Blondin, P | 2 |
| Jardin, A | 10 |
| Hansen, BJ | 7 |
| Mensink, HJ | 5 |
| Walter, S | 2 |
| Meyhoff, HH | 5 |
| Larosa, M | 1 |
| Ferretti, S | 1 |
| Salsi, P | 1 |
| Simonazzi, M | 1 |
| Bensadoun, H | 4 |
| Delauche-Cavallier, MC | 8 |
| Stalla-Bourdillon, A | 1 |
| Attali, P | 5 |
| Milani, M | 1 |
| Mautone, A | 1 |
| Tucci, G | 1 |
| Gentili, G | 1 |
| Chisena, S | 1 |
| Mandressi, A | 1 |
| Zaroli, A | 1 |
| Belloni, M | 1 |
| Antonelli, D | 1 |
| Bernasconi, S | 1 |
| Buizza, C | 1 |
| Schulman, CC | 1 |
| De Sy, W | 1 |
| Vandendris, M | 1 |
| Tomas, M | 1 |
| Santoni, JP | 2 |
| Flyger, H | 3 |
| Brasso, K | 1 |
| Schou, J | 1 |
| Thorup Andersen, J | 1 |
| Mortensen, S | 3 |
| Hald, T | 2 |
| Wilde, MI | 1 |
| Fitton, A | 1 |
| McTavish, D | 1 |
| Martelli, A | 1 |
| Pacifico, P | 2 |
| Casadei, G | 2 |
| McCarthy, C | 4 |
| Grange, JC | 6 |
| Portet-Brunet, L | 1 |
| MacCarthy, C | 1 |
| Du Boys, B | 1 |
| Grippon, P | 1 |
| Lassale, C | 1 |
| Leplège, A | 1 |
| Thibault, P | 2 |
| Mogensen, P | 1 |
| Larsen, EH | 1 |
| Roth, S | 2 |
| Geffriaud-Ricouard, C | 4 |
| Martorana, G | 1 |
| Giberti, C | 1 |
| Di Silverio, F | 1 |
| von Heland, M | 1 |
| Rigatti, P | 1 |
| Colombo, R | 1 |
| Gómez Sancha, F | 1 |
| Fernández Arjona, M | 1 |
| Peinado Ibarra, F | 1 |
| Fernández Borrell, A | 1 |
| Mínguez Martínez, R | 1 |
| Pereira Sanz, I | 1 |
| Fonteyne, E | 1 |
| Kontturi, M | 1 |
| Witjes, WP | 3 |
| Khan, A | 1 |
| Comet, D | 5 |
| Riehmann, M | 1 |
| Hendolin, N | 1 |
| Zerbib, M | 1 |
| Vignoli, GC | 1 |
| Geffriaud, C | 1 |
| Debruyne, FM | 2 |
| Wijkstra, H | 1 |
| Mazo, EB | 1 |
| Matushevskiĭ, IA | 1 |
| Nikitin, IuIu | 1 |
| Chapple, CR | 2 |
| Delauche Cavallier, MC | 1 |
| Martin, D | 1 |
| Angel, I | 1 |
| Reis, RB | 1 |
| Cologna, A | 1 |
| Suaid, HJ | 1 |
| Martins, AC | 1 |
| Kohn, IJ | 1 |
| Colloi, D | 1 |
| Resel, L | 1 |
| Vela-Casasempere, P | 1 |
| Borras-Blasco, J | 1 |
| Navarro-Ruiz, A | 1 |
| Bèïque, L | 1 |
| Por, CP | 1 |
| Evans, MF | 1 |
| Djavan, B | 1 |
| Marberger, M | 1 |
| Mc Carthy, C | 1 |
| Höfner, K | 2 |
| Claes, H | 1 |
| Folkestad, B | 1 |
| Speakman, MJ | 1 |
| Daruwala, PD | 1 |
| Mitchell, ID | 1 |
| Shearer, MG | 1 |
| Laval, KU | 2 |
| van Cangh, P | 2 |
| Sánchez-Chapado, M | 2 |
| Guil, M | 2 |
| Alfaro, V | 2 |
| Badiella, L | 1 |
| Fernández-Hernando, N | 2 |
| Vela Navarrete, R | 1 |
| Gabriel, R | 1 |
| Barajas, R | 1 |
| Ausín, I | 1 |
| Fourcade, RO | 1 |
| Clifford, GM | 1 |
| Farmer, RD | 2 |
| Badiella, LI | 1 |
| Santoni, J | 1 |
| Van Kerrebroeck, PE | 1 |
| Souverein, PC | 1 |
| Herings, RM | 1 |
| Man in 't Veld, AJ | 1 |
| Leufkens, HG | 1 |
| Costantino, G | 1 |
| Clementi, G | 1 |
| Matera, M | 1 |
| Dutkiewics, S | 1 |
| Flannery, MT | 1 |
| Narayan, P | 1 |
| Chess-Williams, R | 1 |
| McKeage, K | 1 |
| Plosker, GL | 1 |
| Kortmann, BB | 1 |
| Rossi, C | 1 |
| Sonke, GS | 1 |
| Floratos, DL | 1 |
| Kiemeney, LA | 1 |
| van Kerrebroec, P | 1 |
| Jonas, U | 1 |
| Morita, T | 1 |
| Kondo, S | 1 |
| Teillac, P | 1 |
| Carbin, BE | 1 |
| Bauer, P | 1 |
| Friskand, M | 1 |
| Moyse, D | 1 |
| Ramsay, JW | 1 |
| Scott, GI | 1 |
| Whitfield, HN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT03314025] | Phase 2 | 158 participants (Anticipated) | Interventional | 2017-10-06 | Recruiting | ||
| The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia[NCT03144596] | Phase 4 | 63 participants (Actual) | Interventional | 2015-10-29 | Completed | ||
| The Long Term Effects of Alfuzosin (Xatral XL) in LUTS/BPH Patients: Evaluation of Symptom-specific Goal Achievement According to Symptom Improvement, Bladder Outlet Obstruction Grade and Bladder Contractility[NCT00836823] | Phase 4 | 130 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Long-Term, Efficacy and Safety of Alfuzosin 10 MG OD on the Risk of Acute Urinary Retention and the Need for Surgery in Patients With BPH. A Two Year, Randomized, Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study.[NCT00029822] | Phase 3 | 1,522 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Research on Benefit of Umooze as Add-on Therapy in Benign Prostatic Hyperplasia[NCT02313233] | 41 participants (Actual) | Interventional | 2013-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
It's 7- item urinary symptom severity scale. The answers are assigned points from 0 to 5, indicating increasing severity. The total score can therefore range from 0 to 35 points. (NCT02313233)
Timeframe: 56 days
| Intervention | units on a scale (Mean) | |
|---|---|---|
| International prostate symptom score | Difference in IPSS between V1 and V6 | |
| Placebo | 13.6 | -5.94 |
| Umooze | 9.83 | -3.39 |
It's 7- item urinary symptom severity scale. The answers are assigned points from 0 to 5, indicating increasing severity. The total score can therefore range from 0 to 35 points. (NCT02313233)
Timeframe: 56 days
| Intervention | units on a scale (Mean) | |
|---|---|---|
| International prostate symptom score | Difference in IPSS between V1 and V6 | |
| Placebo | 14.33 | -4.33 |
| Umooze | 11.00 | -9.50 |
It's used to determine the degree of urinary difficulty. (NCT02313233)
Timeframe: 56 days
| Intervention | ml/ sec (Mean) | |
|---|---|---|
| Qmax | Difference of Qmax between V1 and V6 | |
| Placebo | 12.72 | 2.49 |
| Umooze | 14.4 | 2.88 |
The PVR urine test measures the amount of urine left in the bladder after urination. (NCT02313233)
Timeframe: 56 days
| Intervention | ml (Mean) | |
|---|---|---|
| Post- Void Residual Volume (PVR) | Difference of PVR between V1 and V6 | |
| Placebo | 67.2 | 14.8 |
| Umooze | 35.3 | -8.39 |
It's related to progression of benign prostatic hyperplasia (BPH). (NCT02313233)
Timeframe: 56 days
| Intervention | cm^3 (Mean) | |
|---|---|---|
| Prostate Volume | Difference of prostate volume between V1 and V6 | |
| Placebo | 38.2 | -1.33 |
| Umooze | 29.1 | -8.17 |
Serum PSA test measures the amount of prostate- specific antigen in the blood. As a man's prostate enlarges with age, the amount of PSA in the blood normally increases. (NCT02313233)
Timeframe: 56 days
| Intervention | ng/ml (Mean) | |
|---|---|---|
| Prostate- specific Antigen (PSA) | Difference of PSA between V1 and V6 | |
| Placebo | 2.22 | 0.26 |
| Umooze | 1.67 | 0.14 |
The Quality of Life (QoL) is a single question with scores of 0~6 point and corresponding to the assessment index ranging from delighted to terrible. (NCT02313233)
Timeframe: 56 days
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Quality of Life (QoL) | Difference of QoL between V1 and V6 | |
| Placebo | 3.27 | -0.09 |
| Umooze | 2.73 | -0.82 |
The QoL index is a single question with scores of 0~6 point and corresponding to the assessment index ranging from delighted to terrible. (NCT02313233)
Timeframe: 56 days
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Quality-of-Life (QoL) | Difference of QoL between V1 and V6 | |
| Placebo | 3.22 | -0.56 |
| Umooze | 2.72 | -0.61 |
39 reviews available for alfuzosin and Adenoma, Prostatic
| Article | Year |
|---|---|
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlle | 1997 |
Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Indoles; Lower Urinary Tract Symptoms; Male; | 2017 |
[LUTS in BPH patients : Comparison of silodosin versus tamsulosin, naftopidil, alfuzosin and placebo for the treatment of lower urinary tract symptoms].
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Naphth | 2019 |
Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.
Topics: Apoptosis; Dutasteride; Endocrine System; Finasteride; Humans; Male; Prostatic Hyperplasia; Quinazol | 2016 |
[Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Evidence-Based Medicine; Humans; Male; Prazosin; Prostatic | 2008 |
Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily.
Topics: Adrenergic alpha-Antagonists; Aged; Aging; Dose-Response Relationship, Drug; Drug Administration Sch | 2008 |
Watchful waiting in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Disease Progression; Humans; Male; Prostate; Prostate-Specific Antigen | 2009 |
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inh | 2009 |
The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews.
Topics: Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Humans; Male; Naphthalenes; Piperazines; Prostat | 2013 |
Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood-Brain Barrier; Doxazosin; Humans; Male; | 2001 |
Current treatment options for benign prostatic hyperplasia and their impact on sexual function.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Erectile Dysfunction; Finasteride; Human | 2003 |
Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Delayed-Action Preparations; Drug Interactio | 2003 |
[Pharmacologic treatment of benign prostatic hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasterid | 2003 |
Alfuzosin for the management of benign prostate hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; | 2003 |
Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administra | 2004 |
Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Hum | 2004 |
Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines; Randomized Controll | 2005 |
Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quality of Life; Quinazolines; Se | 2006 |
Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic Hyperpla | 2006 |
The natural history of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Aged, 80 and over; Controlled Clinical Trials as To | 2006 |
Definition of at-risk patients: dynamic variables.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Disease Progression; Humans; M | 2006 |
Effects of alpha(1)-adrenoceptor antagonists on male sexual function.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Antagonists; Adult; Aged; Doxazosin; Ejaculation | 2006 |
Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Huma | 2006 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Co | 2006 |
Clinical results with alpha-blockers in patients with symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Controlled Clinical Trials as Topic; Humans; Male; Multicenter Studies | 1994 |
Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines | 1993 |
Using a large clinical database to assess the effectiveness of alfuzosin.
Topics: Adrenergic alpha-Antagonists; Aged; Cost-Benefit Analysis; Databases, Factual; Decision Making, Comp | 1997 |
[Alpha blockers in the treatment of benign hyperplasia of the prostate].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Indoramin; Male; Phenoxybenzamine; Prazosin; Prosta | 1997 |
Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Delayed-Action Preparations; Humans; Hypotension, Orth | 1998 |
Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Hormones; Humans; Male; Patient S | 1998 |
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Dizzines | 1999 |
Medical therapy for benign prostatic hyperplasia: a review of the literature.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Indoramin; Male; Prazosin; Prostatic H | 2000 |
Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
Topics: Adrenergic alpha-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Humans; Male; Middle Aged | 2001 |
Does acute urinary retention respond to alpha-blockers alone?
Topics: Acute Disease; Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines; Trea | 2001 |
Worldwide experience with alfuzosin and tamsulosin.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Controlled Clinical Trials as Topic; Hu | 2001 |
Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Prostatic Hyperplasi | 2001 |
The use of alpha-adrenoceptor antagonists in lower urinary tract disease.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines; Sulfo | 2002 |
Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
Topics: Absorption; Adrenergic alpha-Antagonists; Aged; Area Under Curve; Clinical Trials as Topic; Delayed- | 2002 |
Alfuzosin: a clinically uroselective alpha1-blocker.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Animals; Clinical Trials, Phase III as Top | 2002 |
72 trials available for alfuzosin and Adenoma, Prostatic
| Article | Year |
|---|---|
The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases with Benign Prostatic Hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Choroid; Color Vision; Diagnostic | 2017 |
Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Prospecti | 2013 |
A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Aged; Device Removal; Humans; Male; Middle A | 2014 |
Prospective masked comparison of intraoperative floppy iris syndrome severity with tamsulosin versus alfuzosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cross-Sectional Studies; Double-Blind Method; Humans; | 2014 |
Is the double dose alpha-blocker treatment superior than the single dose in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia?
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Dizziness; Drug Therapy, Combinati | 2014 |
Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive med
Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Humans; Hypertension; Lowe | 2015 |
Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Prostatic Hype | 2009 |
An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Ejaculation; Humans; Male; Middle Aged; Patient Satis | 2010 |
Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Ejaculation; Erectile Dysfunction; Humans; Male; Midd | 2010 |
Most bothersome symptom and symptom specific goal achievement in patients with benign prostatic obstruction: a prospective open label study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Goals; Humans; Male; Middle Aged; Prospective Studies; Pros | 2011 |
The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Muscle | 2011 |
Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cross-Over Studies; Humans; Male; Middle Aged; Prosta | 2011 |
Effects of pulsed electromagnetic fields on benign prostate hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Electromagnetic Fields; Humans; Male; Organ Size; Pro | 2011 |
Treatment with a uroselective α1-blocker improves voiding and sexual function: a study in Thai men with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Erectile Dysfunction; Humans; Male; Middle Aged; Peni | 2011 |
Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Drug Therapy, Combination; Humans; Male; Middl | 2012 |
Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Analysis of Variance; A | 2002 |
Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Biological Availability; Biopsy, Needle; D | 2003 |
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Erectile Dysfunct | 2003 |
First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Dru | 2003 |
Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Doxazosin; Drug Administration Schedule; Humans; | 2004 |
Prostate size influences the outcome after presenting with acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Cohort Studies; Follow-Up Studies; Humans; Male; | 2004 |
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Biomarkers; Combined Modality Therapy; Disease-Fr | 2005 |
Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blin | 2005 |
Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Confidence Intervals; Dose-Response Relations | 2006 |
Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Double-Blind Method; Humans; Male; Middle A | 2006 |
The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Male; Middle Aged; Pain; Prostatic Hyperpla | 2006 |
Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Placebos; Prosta | 2007 |
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; M | 2007 |
The effects of two systemic alpha1-adrenergic blockers on pupil diameter: a prospective randomized single-blind study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Humans; Intraoperative | 2007 |
A prospective pilot study to validate the management protocol for patients presenting with acute urinary retention: a community-based, nonhospitalised protocol.
Topics: Adrenergic alpha-Antagonists; Aged; Catheterization; Community Health Services; Humans; Male; Middle | 2006 |
Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Age | 1993 |
[Alfuzosin in the treatment of benign prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quality of Life; Quinazolines; Ur | 1993 |
Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperp | 1994 |
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Follow-Up Studies; Heart Rate; Humans; Long-Term | 1994 |
[Assessment of the effects of alfuzosin on miction with dynamic echography].
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Prostatic Hyperplasia; Quinazolines | 1994 |
Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. The Italian Alfuzosin Cooperative Group.
Topics: Activities of Daily Living; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Analysis o | 1995 |
Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Cross-Over Studies; Double-Blind Method; Humans; Male; Mi | 1994 |
Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic H | 1995 |
Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Italian Alfuzosin Co-Operative Group.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Lif | 1993 |
Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Aged; Cohort Studies; Follow-Up Studies; Humans; Male; Prospective Stu | 1993 |
Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Follow-Up Studies; Humans; Male; Middle Aged; | 1996 |
Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Evaluation; Follow-Up Studies; France; Humans; Male; Produc | 1996 |
Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Family Practice; Humans; Male; Middle Aged; | 1996 |
Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Denmark; Double-Blind Method; Drug Administra | 1996 |
Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Delayed-Action Preparations; | 1997 |
Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases | 1997 |
Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Follow-Up Studies; Human | 1997 |
Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Male; Middle Aged; Prostatic Hyperplasia | 1997 |
Comparison of the Danish Prostatic Symptom Score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Hyperthermia, Induced; Male; Microwaves; | 1998 |
Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Aged; Family Practice; Follow-Up Studies; Humans; Male; Middle Aged; P | 1998 |
Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperp | 1998 |
Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Delayed-Action Preparations; Doubl | 1998 |
Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia?
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Double-Blind Method; Humans; Hypotension; Mal | 1998 |
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperp | 1993 |
[Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years wi alfuzosin in general practice. BPH Group in General Practice].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Follow-Up Studies; France; Hu | 1999 |
Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combinati | 1999 |
Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; Follow-Up Studie | 1999 |
History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years.
Topics: Adrenergic alpha-Antagonists; Aged; Cohort Studies; Disease Progression; Family Practice; Follow-Up | 2000 |
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Delayed-Action Preparations; Double-Blind Method; Drug Administr | 2000 |
Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice.
Topics: Adrenergic alpha-Antagonists; Aged; Analysis of Variance; Blood Pressure Monitoring, Ambulatory; Del | 2000 |
Safety, efficacy and impact on Patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. The Italian Alfuzosin Co-Operative Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic Hyperpla | 2000 |
[Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Ambulatory Care; Double-Blind Method; Humans; | 2000 |
The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Age Factors; Aged; Humans; Male; Middle Aged; Prostatic Hyperpl | 2000 |
The efficacy and safety of a new once-a-day formulation of an alpha-blocker.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Prostat | 2001 |
[Long-term therapy of benign prostatic hyperplasia. Our experience].
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Finasteride; Follow-Up Studies; Humans; Male; Mepartr | 2001 |
Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Canada; Double-Blind | 2001 |
Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; Dose-Response Re | 2002 |
Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blin | 1992 |
Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Evaluation; Humans; Male; Middle Aged; P | 1991 |
Efficacy of alfuzosine (an alpha 1-adrenoreceptor blocking drug) in benign hyperplasia of the prostate.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperp | 1991 |
A double-blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outflow obstruction.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Middle Aged; Pro | 1985 |
[Efficacy of an alpha-blocker, alfuzosin, on urinary disorders in men with prostatic adenoma. Intermediate results of a European multicenter study].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Europe; Huma | 1988 |
75 other studies available for alfuzosin and Adenoma, Prostatic
| Article | Year |
|---|---|
Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Cell Line; Dogs; Heterocyclic Compounds, 3-Ri | 2000 |
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Cell Line; Dogs; Dox | 2001 |
[The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)].
Topics: Adrenergic alpha-Antagonists; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Qua | 2022 |
Evaluation of syncope association with α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Doxazosin; Humans; Hypertension; Indoles; Male; Midd | 2019 |
[The use of alfuzosin in the treatment of patients with acute urinary retention].
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Pro | 2020 |
Linh Phu Khang Tue Tinh inhibited prostate proliferation in rats induced benign prostatic hyperplasia by testosterone propionate.
Topics: 5-alpha Reductase Inhibitors; Animals; Dutasteride; Male; Medicine, East Asian Traditional; Prostati | 2021 |
Simultaneous HPLC determination of alfuzosin, tamsulosin and vardenafil in human plasma and pharmaceutical formulations using time programmed fluorescence detection.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Chromatography, High Pressure Liquid; Drug Co | 2019 |
Successful reversal of isolated delayed spinal cord ischemia following endovascular abdominal aneurysm repair.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Angiography, Digital Subtraction; Aortic Aneurysm, Ab | 2019 |
Alpha-1 adrenergic antagonists induced severe rhinitis in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cerebrospinal Fluid Rhinorrhea; Doxazosin; Humans; Ma | 2014 |
Effects of medical therapy or surgery on prostatic and bladder resistive indices in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Middle Ag | 2015 |
The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Middle Ag | 2015 |
The relationship between lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: the role of autonomic hyperactivity.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Autonomic Nervous System; Blood Glucose; Body Mass In | 2014 |
Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Topics: Administrative Claims, Healthcare; Adrenergic alpha-Antagonists; Aged; Benzofurans; Doxazosin; Drug | 2015 |
[Impact of alfuzosin 10 mg once daily on quality of life in Tunisian patients with lower urinary symptoms suggestive of benign prostatic hyperplasia].
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Male; Middle Aged; Prospective Studies; Prost | 2015 |
The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study.
Topics: Accidental Falls; Adrenergic alpha-1 Receptor Antagonists; Aged; Canada; Craniocerebral Trauma; Frac | 2015 |
Modified corneal incisions in intraoperative floppy iris syndrome (IFIS)-prone patients.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Cornea; Drug Combinations; Humans; | 2016 |
The effect of various alpha1-adrenergic receptor antagonists on pupillary dilation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Doxazosin; Humans; Iris Disea | 2008 |
Intraoperative floppy-iris syndrome associated with systemic alpha blockers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cataract Extraction; Doxazosi | 2008 |
Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Ejaculati | 2009 |
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Azasteroids; Capsules; Cholestenone 5 alpha-Redu | 2010 |
Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Doxazosin; Drug Combina | 2010 |
Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Coagulation; Blood Pressure; Brachial Artery; Doxazosin; E | 2011 |
Alfuzosin induced thrombocytopenia after treatment for benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Male; Prostatic Hyperplasia; Quinazolines; Th | 2010 |
Prescriber monitoring for benign prostatic hyperplasia within a family medicine clinic: a comparison of medication classes.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combinati | 2012 |
The effect of alpha antagonists on pupil dynamics: implications for the diagnosis of intraoperative floppy iris syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Case-Control Studies; Cataract Extraction; Diagnostic Techn | 2012 |
Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia.
Topics: Aged; Drug Administration Schedule; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male | 2012 |
Reversible visual loss caused by combination therapy of alfuzosin and finasteride in a patient with uveitic glaucoma.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Drug | 2013 |
The efficacy of alfuzosin treatment in patients with prostatism.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic | 2001 |
Benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Enzyme | 2003 |
Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum.
Topics: Adrenergic alpha-Antagonists; Animals; Erectile Dysfunction; Male; Muscle Relaxation; Penile Erectio | 2003 |
Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adolescent; Adult; Advisory Committees; Anti-Infective Agents; | 2003 |
Clinical and pressure-flow changes after long-term treatment with alfuzosin SR.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazo | 2003 |
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Prostatic Hyperplasia; Quinazolines | 2003 |
Alfuzosin (uroxatral)--another alpha1-blocker for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Contraindications; Drug Interactions; Humans | 2004 |
A current review of medical therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Dr | 2004 |
On call. My doctor gave me a prescription for Uroxatral to treat my enlarged prostate. I tried to look up this medicine in your Harvard Medical School Guide to Men's Health, but I couldn't find it. What can you tell me about Uroxatral?
Topics: Adrenergic beta-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines | 2004 |
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Doxazosin; | 2004 |
Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Drug Administration Sch | 2005 |
The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Decision Support Techniques; Drug Costs; Emergency Treatm | 2005 |
Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin.
Topics: Adrenergic alpha-Antagonists; Delayed-Action Preparations; Humans; Male; Middle Aged; Prostatic Hype | 2005 |
Effects of selective alpha-1-adrenergic receptor blockers on bladder weight.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Humans; Hypertrophy; Ma | 2006 |
Are all alpha-blockers created the same?
Topics: Adrenergic alpha-Antagonists; Adult; Clinical Trials as Topic; Dizziness; Doxazosin; Humans; Male; M | 2006 |
Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Disease Progression; Humans; Male; Prostatic Hyperplasia; Quinazolines | 2006 |
Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Libido; Male; Middle Aged; Patient Satisfac | 2006 |
Intraoperative floppy iris syndrome in a patient taking alfuzosin for benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Aged, 80 and over; Cataract Extraction; Humans; Intraoperative Complic | 2006 |
The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Catheters, Indwelling; | 2006 |
Toxic epidermal necrolysis caused by alfuzosin, an alpha1-adrenoceptor antagonist.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Diagnosis, Differential; Exanthema; Fever; Hu | 2006 |
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middl | 2006 |
Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Drug Therapy, Combination; Enzyme Inhibitors; Erect | 2007 |
Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha1-adrenoceptor antagonist.
Topics: Administration, Topical; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adul | 2007 |
Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Endosonography; Humans; Male; | 2007 |
Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Humans; Incidence; Intr | 2007 |
Alfuzosin-induced acute liver injury.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Chemical and Drug Induced Liver Injury; Dysuria; Humans | 2007 |
Potentiometric sensors enabling fast screening of the benign prostatic hyperplasia drug alfuzosin in pharmaceuticals, urine and serum.
Topics: Drug Evaluation, Preclinical; Electrochemistry; Electrodes; Humans; Hydrogen-Ion Concentration; Male | 2007 |
Comparing the therapeutic outcome of different alpha-blocker treatments for BPH in the same individuals.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prazosin; Prostate | 2008 |
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Erectile Dysfunction; Humans; Male; Nocturi | 2008 |
[Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience].
Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostati | 1994 |
[Alfuzosin in benign prostatic hyperplasia. A new principle is evaluated. Report of a study].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Humans; Male | 1995 |
[Alpha blockers, TUS-P and TUR-P in the treatment of benign prostatic hypertrophy. A comparison using multivariate statistical analysis].
Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analy | 1995 |
Re: Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines | 1996 |
[Drugs for prostatic adenoma].
Topics: Adrenergic alpha-Antagonists; Drug Monitoring; Enzyme Inhibitors; Finasteride; Humans; Male; Prostat | 1995 |
Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Anxiety; Case-Control Studies; Cohort | 1997 |
Computerized artifact detection and correction of uroflow curves: towards a more consistent quantitative assessment of maximum flow.
Topics: Adrenergic alpha-Antagonists; Computer Simulation; Humans; Male; Models, Biological; Observer Variat | 1998 |
[The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Evaluation; Humans; Male; Middle Aged; P | 1997 |
Clinical uroselectivity: evidence from patients treated with slow release alfuzosin for symptomatic benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Delayed-Action Preparations; Dose-Response Re | 1998 |
Alfuzosin-associated dermatomyositis.
Topics: Adrenergic alpha-Antagonists; Aged; Dermatomyositis; Humans; Magnetic Resonance Imaging; Male; Muscl | 1998 |
One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Family Practice; Follow-Up Studies; Humans; M | 2000 |
[Prostatic benign hypertrophy: review of effectiveness, tolerance, and impact on quality of life of prolonged treatment with alfuzosin].
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Prostatic Hyperplasia; Quality of Life; Quinazolin | 2000 |
Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Aged; Bias; Cardiovascular Diseas | 2001 |
Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Middle | 2001 |
Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.
Topics: Adrenergic beta-Antagonists; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyper | 2002 |
[Alfuzosin. A new selective alpha 1 receptor antagonist for symptomatic medical treatment of benign prostatic hypertrophy prior to surgery].
Topics: Adrenergic alpha-Antagonists; Humans; Male; Premedication; Preoperative Care; Prostatectomy; Prostat | 1992 |
[Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas].
Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Piperazines; Prazosin; Prostatic Hyperpla | 1992 |
Alfuzosin for benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Drug Administration Schedule; Humans; Male; Prazosin; Prostatic Hyperp | 1991 |
Alfuzosin for benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines | 1991 |